Multicenter, open-label, nonrandomized, observational safety study in subjects using insulin aspart in basal-bolus regimen for the treatment of diabetes
| Autor: | Janusz, Krzymień, Teresa, Kobli, Maciej, Nazar |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Blood Glucose Glycated Hemoglobin Male Adolescent Dose-Response Relationship Drug Incidence Comorbidity Middle Aged Drug Administration Schedule Hypoglycemia Young Adult Diabetes Mellitus Type 1 Treatment Outcome Diabetes Mellitus Type 2 Humans Hypoglycemic Agents Insulin Female Poland Insulin Aspart Aged |
| Zdroj: | Polskie Archiwum Medycyny Wewnetrznej. 120(11) |
| Popis: | Basal-bolus insulin therapy is a standard method of intensifying diabetes treatment. A common adverse effect of such treatment is hypoglycemia. Data on frequency of hypoglycemia when fast-acting insulin analogue is used in everyday clinical practice is scarce.The aim of the study was to investigate the risk of hypoglycemia after the use of insulin aspart in basal-bolus therapy in patients with type 1 and 2 diabetes.It was a multicenter, open-label, noninterventional study. It involved 950 patients with type 1 and 1332 patients with type 2 diabetes who started preprandial insulin aspart in basal-bolus regimen. Patients were followed for 13 weeks. The primary endpoint was the incidence of major daytime and nocturnal hypoglycemic events assessed on the basis of patients' self-reports during follow-up compared with a 4-week period before the baseline visit. Secondary endpoints were: incidence of minor daytime and nocturnal hypoglycemia, hemoglobin A1c (HbA1c), fasting and postprandial glycemia.The rate of major hypoglycemia decreased in patients with type 1 diabetes--the incidence rate ratio (IRR) was 0.14 for daytime and 0.03 for nocturnal episodes (P0.0001) and did not change in patients with type 2 diabetes. The rate of minor episodes decreased in patients with type 1 diabetes (IRR = 0.44 for daytime and IRR = 0.24 for nocturnal episodes, P0.0001) and in patients with type 2 diabetes (IRR= 0.57, P0.0001 for daytime and IRR = 0.89, P0.05 for nocturnal episodes). HbA1c decreased by 1.28 ± 1.64% in type 1 and 1.25 ± 1.10% in type 2 diabetes (both P0.0001). Self-measured fasting and postprandial blood glucose levels were significantly lower at the final visit compared with baseline, irrespective of diabetes type.In clinical practice, treatment with insulin aspart in basal-bolus regimen is associated with low risk of hypoglycemia and leads to a significant improvement in glucose control, irrespective of diabetes type. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|